ME02520B - Farmaceutske kompozicije - Google Patents
Farmaceutske kompozicijeInfo
- Publication number
- ME02520B ME02520B MEP-2016-192A MEP19216A ME02520B ME 02520 B ME02520 B ME 02520B ME P19216 A MEP19216 A ME P19216A ME 02520 B ME02520 B ME 02520B
- Authority
- ME
- Montenegro
- Prior art keywords
- pharmaceutical compositions
- pharmaceutical
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38354110P | 2010-09-16 | 2010-09-16 | |
| PCT/US2011/051713 WO2012037320A2 (en) | 2010-09-16 | 2011-09-15 | Pharmaceutical compositions |
| EP11825920.9A EP2616076B1 (en) | 2010-09-16 | 2011-09-15 | Pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02520B true ME02520B (me) | 2017-02-20 |
Family
ID=45832235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2016-192A ME02520B (me) | 2010-09-16 | 2011-09-15 | Farmaceutske kompozicije |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US20130171214A1 (me) |
| EP (1) | EP2616076B1 (me) |
| JP (1) | JP6231385B2 (me) |
| KR (1) | KR101938662B1 (me) |
| CN (1) | CN103547266B (me) |
| AU (1) | AU2011302030B2 (me) |
| BR (1) | BR112013005907B1 (me) |
| CA (1) | CA2810524C (me) |
| CL (1) | CL2013000715A1 (me) |
| CY (1) | CY1118279T1 (me) |
| DK (1) | DK2616076T3 (me) |
| EA (1) | EA024924B1 (me) |
| ES (1) | ES2594557T3 (me) |
| HR (1) | HRP20161280T1 (me) |
| HU (1) | HUE031336T2 (me) |
| IL (1) | IL225028A (me) |
| LT (1) | LT2616076T (me) |
| ME (1) | ME02520B (me) |
| MX (1) | MX346193B (me) |
| PL (1) | PL2616076T3 (me) |
| PT (1) | PT2616076T (me) |
| RS (1) | RS55222B1 (me) |
| SI (1) | SI2616076T1 (me) |
| SM (1) | SMT201600350B (me) |
| TW (1) | TWI577377B (me) |
| UA (1) | UA108250C2 (me) |
| WO (1) | WO2012037320A2 (me) |
| ZA (1) | ZA201301766B (me) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3387B1 (ar) | 2011-12-16 | 2019-03-13 | Glaxosmithkline Llc | مشتقات بيتولين |
| BR112015013695A2 (pt) * | 2012-12-14 | 2017-07-11 | Glaxosmithkline Llc | composição farmacêutica, e, métodos para tratamento e para prevenção de uma infecção por hiv |
| US9808428B2 (en) | 2014-01-14 | 2017-11-07 | Board Of Regents Of The University Of Nebraska | Compositions and methods for the delivery of therapeutics |
| WO2015127437A1 (en) * | 2014-02-24 | 2015-08-27 | The Board Of Regents Of The University Of Nebraska | Compositions and methods for the delivery of therapeutics |
| JP2017528497A (ja) | 2014-09-26 | 2017-09-28 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | 長時間作用型医薬組成物 |
| EP3203995A4 (en) | 2014-10-09 | 2019-05-15 | Board of Regents of the University of Nebraska | COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS |
| MD20170071A2 (ro) * | 2014-12-20 | 2017-09-30 | Troikaa Pharmaceuticals Limited | Compoziţii injectabile de paracetamol |
| WO2017223280A2 (en) * | 2016-06-23 | 2017-12-28 | Viiv Healthcare Company | Compositions and methods for the delivery of therapeutics |
| WO2018175271A1 (en) * | 2017-03-24 | 2018-09-27 | Merck Sharp & Dohme Corp. | Formulation for parenteral administration |
| JP2020527570A (ja) * | 2017-07-18 | 2020-09-10 | ヴィーブ ヘルスケア カンパニー | 組み合わせ薬物療法 |
| CA3126348A1 (en) | 2018-01-12 | 2020-07-18 | Board Of Regents Of The University Of Nebraska | Antiviral prodrugs and formulations thereof |
| CA3132832A1 (en) | 2018-04-09 | 2019-10-17 | Howard E. Gendelman | Antiviral prodrugs and formulations thereof |
| MX2021004679A (es) | 2018-10-22 | 2021-07-15 | Univ Nebraska | Profarmacos antivirales y nanoformulaciones de las mismas. |
| CN109646440B (zh) * | 2019-01-11 | 2021-04-20 | 山东省农业科学院奶牛研究中心 | Cabotegravir在制备抗牛传染性鼻气管炎药物中的应用 |
| BR112021018827A2 (pt) | 2019-03-22 | 2021-11-23 | Gilead Sciences Inc | Compostos de carbamoilpiridona tricíclica em ponte e seu uso farmacêutico |
| KR20220112771A (ko) * | 2019-12-09 | 2022-08-11 | 비이브 헬쓰케어 컴퍼니 | 카보테그라비르를 포함하는 제약 조성물 |
| EP4110783A1 (en) | 2020-02-24 | 2023-01-04 | Gilead Sciences, Inc. | Tetracyclic compounds for treating hiv infection |
| EP4178540A1 (en) * | 2020-07-09 | 2023-05-17 | JANSSEN Pharmaceutica NV | Long-acting formulations |
| EP4208169A1 (en) * | 2020-09-01 | 2023-07-12 | VIIV Healthcare Company | Combination of cabotegravir and levonorgestrel |
| WO2022079739A1 (en) | 2020-10-14 | 2022-04-21 | Cipla Limited | Fixed dose compositions of cabotegravir and rilpivirine |
| HUE064467T2 (hu) | 2021-01-19 | 2024-03-28 | Gilead Sciences Inc | Szubsztituált piridotriazin-származékok és alkalmazásuk |
| CN115844838B (zh) * | 2022-12-01 | 2023-10-24 | 浙江萃泽医药科技有限公司 | 一种可注射的药物组合物 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1215599A (fr) * | 1958-06-27 | 1960-04-19 | Rhone Poulenc Sa | Nouveaux dérivés de l'iminodibenzyle substitués à l'azote par une chaîne pipérazinique et leur préparation |
| US5352459A (en) | 1992-12-16 | 1994-10-04 | Sterling Winthrop Inc. | Use of purified surface modifiers to prevent particle aggregation during sterilization |
| US5484926A (en) | 1993-10-07 | 1996-01-16 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
| KR100571215B1 (ko) | 1995-06-07 | 2006-10-24 | 트라이머리스 인코퍼레이티드 | 복합적인치료요법을이용한hiv와다른바이러스감염의치료 |
| TW487572B (en) | 1996-05-20 | 2002-05-21 | Janssen Pharmaceutica Nv | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
| TW518218B (en) * | 1999-05-27 | 2003-01-21 | Merck Patent Gmbh | Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders |
| JP5160005B2 (ja) * | 2000-12-28 | 2013-03-13 | 武田薬品工業株式会社 | 徐放性製剤 |
| JP2006506442A (ja) * | 2002-07-09 | 2006-02-23 | ポイント セラピューティクス， インコーポレイテッド | ボロプロリン化合物併用療法 |
| JP2007501683A (ja) | 2003-05-22 | 2007-02-01 | エラン ファーマ インターナショナル リミテッド | γ線照射によるナノ粒子活性物質分散体の滅菌法 |
| WO2006114384A1 (en) | 2005-04-25 | 2006-11-02 | Janssen Pharmaceutica N.V. | Preparation of aseptic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyridio[1,2-a]pyrimidin-4-one palmitate ester |
| PL3284520T3 (pl) * | 2005-04-28 | 2020-01-31 | Viiv Healthcare Company | Policykliczna pochodna karbamoilopirydonu mająca aktywność hamowania integrazy HIV |
| US7601355B2 (en) * | 2005-06-01 | 2009-10-13 | Northwestern University | Compositions and methods for altering immune function |
| KR101501475B1 (ko) * | 2006-01-20 | 2015-03-19 | 얀센 알 앤드 디 아일랜드 | Ｔｍｃ２７８을 이용한 ｈｉｖ 감염의 장기간 요법 |
| US20070178051A1 (en) | 2006-01-27 | 2007-08-02 | Elan Pharma International, Ltd. | Sterilized nanoparticulate glucocorticosteroid formulations |
| EP2175857B1 (en) * | 2007-07-12 | 2013-09-11 | Janssen R&D Ireland | Crystalline form of (e) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
| EP2234617B1 (en) * | 2007-12-19 | 2021-03-31 | Janssen Pharmaceutica NV | Dosing regimen associated with long acting injectable paliperidone esters |
| TWI489994B (zh) | 2008-03-17 | 2015-07-01 | Baxter Healthcare Sa | 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法 |
| WO2009128918A1 (en) * | 2008-04-14 | 2009-10-22 | Halozyme, Inc. | Combination therapy using a soluble hyaluronidase and a bisphosphonate |
| US8648119B2 (en) * | 2008-05-23 | 2014-02-11 | Otonomy, Inc. | Controlled release immunomodulator compositions and methods for the treatment of otic disorders |
| WO2010011815A1 (en) * | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| WO2010011814A1 (en) * | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| CN104788367A (zh) | 2008-12-11 | 2015-07-22 | 盐野义制药株式会社 | 氨甲酰基吡啶酮hiv整合酶抑制剂的方法和中间体 |
| RU2527451C2 (ru) | 2008-12-11 | 2014-08-27 | Вайв Хелткер Компани | Синтез карбамоилпиридоновых ингибиторов интегразы вич и промежуточных соединений |
| WO2011017395A1 (en) | 2009-08-04 | 2011-02-10 | Glaxosmithkline Llc | Chemical compounds |
| US20110152303A1 (en) | 2009-12-18 | 2011-06-23 | Glaxosmithkline Llc | Chemical Compounds |
-
2011
- 2011-09-14 TW TW100133064A patent/TWI577377B/zh active
- 2011-09-15 EA EA201390233A patent/EA024924B1/ru unknown
- 2011-09-15 PL PL11825920T patent/PL2616076T3/pl unknown
- 2011-09-15 KR KR1020137009569A patent/KR101938662B1/ko active IP Right Grant
- 2011-09-15 BR BR112013005907-9A patent/BR112013005907B1/pt active IP Right Grant
- 2011-09-15 CA CA2810524A patent/CA2810524C/en active Active
- 2011-09-15 SI SI201130966A patent/SI2616076T1/sl unknown
- 2011-09-15 MX MX2013003037A patent/MX346193B/es active IP Right Grant
- 2011-09-15 UA UAA201303057A patent/UA108250C2/ru unknown
- 2011-09-15 RS RS20160826A patent/RS55222B1/sr unknown
- 2011-09-15 HU HUE11825920A patent/HUE031336T2/hu unknown
- 2011-09-15 US US13/823,316 patent/US20130171214A1/en not_active Abandoned
- 2011-09-15 PT PT118259209T patent/PT2616076T/pt unknown
- 2011-09-15 ES ES11825920.9T patent/ES2594557T3/es active Active
- 2011-09-15 LT LTEP11825920.9T patent/LT2616076T/lt unknown
- 2011-09-15 JP JP2013529316A patent/JP6231385B2/ja active Active
- 2011-09-15 AU AU2011302030A patent/AU2011302030B2/en active Active
- 2011-09-15 WO PCT/US2011/051713 patent/WO2012037320A2/en active Application Filing
- 2011-09-15 ME MEP-2016-192A patent/ME02520B/me unknown
- 2011-09-15 DK DK11825920.9T patent/DK2616076T3/en active
- 2011-09-15 EP EP11825920.9A patent/EP2616076B1/en active Active
- 2011-09-15 CN CN201180044588.5A patent/CN103547266B/zh active Active
-
2013
- 2013-03-03 IL IL225028A patent/IL225028A/en active IP Right Grant
- 2013-03-07 ZA ZA2013/01766A patent/ZA201301766B/en unknown
- 2013-03-15 CL CL2013000715A patent/CL2013000715A1/es unknown
-
2016
- 2016-10-04 SM SM201600350T patent/SMT201600350B/it unknown
- 2016-10-04 CY CY20161100985T patent/CY1118279T1/el unknown
- 2016-10-05 HR HRP20161280TT patent/HRP20161280T1/hr unknown
- 2016-10-13 US US15/292,394 patent/US11224597B2/en active Active
-
2021
- 2021-12-10 US US17/547,682 patent/US20220096469A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1246170A1 (zh) | 藥物組合物 | |
| ZA201300458B (en) | C-met-modulator pharmaceutical compositions | |
| IL223535A (en) | Solid medicinal compositions | |
| ZA201301766B (en) | Pharmaceutical compositions | |
| IL225457A0 (en) | Pharmaceutical composition | |
| LT2619182T (lt) | Farmacinė kompozicija | |
| ZA201300718B (en) | Pharmaceutical compositions | |
| ZA201207670B (en) | Pharmaceutical compositions | |
| PT2579858E (pt) | Composição farmacêutica que contém ivabradina | |
| ZA201303223B (en) | Pharmaceutical compositions | |
| GB201010453D0 (en) | Pharmaceutical composition | |
| ZA201303177B (en) | Pharmaceutical compositions | |
| IL226554A (en) | Medicinal preparations containing alisporiovir | |
| GB201001911D0 (en) | Pharmaceutical composition | |
| EP2560678A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| ZA201303732B (en) | Pharmaceutical compositions | |
| GB201008590D0 (en) | Pharmaceutical compositions | |
| GB201005403D0 (en) | Novel pharmaceutical compositions | |
| GB201019775D0 (en) | Pharmaceutical composition |